About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Multiple Sclerosis Drugs Market is Forecasted to grow at a CAGR of 3.7% by 2031
Multiple Sclerosis Drugs Market

Multiple Sclerosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Immunomodulators, Immunosuppressants, Interferons, Others), By Route of Administration (Oral, Injectables, Infusions), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores), By Disease Type (Relapsing-remitting MS (RRMS), Primary-progressive MS (PPMS), Secondary-progressive MS (SPMS), Progressive-relapsing MS (PRMS)) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRPH1498DR
Last Updated : November 29, 2022
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Multiple Sclerosis Drugs Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Immunomodulators
        1. By Value
      3. Immunosuppressants
        1. By Value
      4. Interferons
        1. By Value
      5. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectables
        1. By Value
        2. Intramuscular
          1. Intramuscular By Value
        3. Subcutaneous
          1. Subcutaneous By Value
        4. Intravenous
          1. Intravenous By Value
      4. Infusions
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Stores
        1. By Value
    5. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Relapsing-remitting MS (RRMS)
        1. By Value
      3. Primary-progressive MS (PPMS)
        1. By Value
      4. Secondary-progressive MS (SPMS)
        1. By Value
      5. Progressive-relapsing MS (PRMS)
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Immunomodulators
        1. By Value
      3. Immunosuppressants
        1. By Value
      4. Interferons
        1. By Value
      5. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectables
        1. By Value
        2. Intramuscular
          1. Intramuscular By Value
        3. Subcutaneous
          1. Subcutaneous By Value
        4. Intravenous
          1. Intravenous By Value
      4. Infusions
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Stores
        1. By Value
    5. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Relapsing-remitting MS (RRMS)
        1. By Value
      3. Primary-progressive MS (PPMS)
        1. By Value
      4. Secondary-progressive MS (SPMS)
        1. By Value
      5. Progressive-relapsing MS (PRMS)
        1. By Value
    6. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Immunomodulators
          1. By Value
        3. Immunosuppressants
          1. By Value
        4. Interferons
          1. By Value
        5. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectables
          1. By Value
          2. Intramuscular
            1. Intramuscular By Value
          3. Subcutaneous
            1. Subcutaneous By Value
          4. Intravenous
            1. Intravenous By Value
        4. Infusions
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Stores
          1. By Value
      4. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Relapsing-remitting MS (RRMS)
          1. By Value
        3. Primary-progressive MS (PPMS)
          1. By Value
        4. Secondary-progressive MS (SPMS)
          1. By Value
        5. Progressive-relapsing MS (PRMS)
          1. By Value
    7. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Immunomodulators
        1. By Value
      3. Immunosuppressants
        1. By Value
      4. Interferons
        1. By Value
      5. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectables
        1. By Value
        2. Intramuscular
          1. Intramuscular By Value
        3. Subcutaneous
          1. Subcutaneous By Value
        4. Intravenous
          1. Intravenous By Value
      4. Infusions
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Stores
        1. By Value
    5. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Relapsing-remitting MS (RRMS)
        1. By Value
      3. Primary-progressive MS (PPMS)
        1. By Value
      4. Secondary-progressive MS (SPMS)
        1. By Value
      5. Progressive-relapsing MS (PRMS)
        1. By Value
    6. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Immunomodulators
          1. By Value
        3. Immunosuppressants
          1. By Value
        4. Interferons
          1. By Value
        5. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectables
          1. By Value
          2. Intramuscular
            1. Intramuscular By Value
          3. Subcutaneous
            1. Subcutaneous By Value
          4. Intravenous
            1. Intravenous By Value
        4. Infusions
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Stores
          1. By Value
      4. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Relapsing-remitting MS (RRMS)
          1. By Value
        3. Primary-progressive MS (PPMS)
          1. By Value
        4. Secondary-progressive MS (SPMS)
          1. By Value
        5. Progressive-relapsing MS (PRMS)
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Immunomodulators
        1. By Value
      3. Immunosuppressants
        1. By Value
      4. Interferons
        1. By Value
      5. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectables
        1. By Value
        2. Intramuscular
          1. Intramuscular By Value
        3. Subcutaneous
          1. Subcutaneous By Value
        4. Intravenous
          1. Intravenous By Value
      4. Infusions
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Stores
        1. By Value
    5. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Relapsing-remitting MS (RRMS)
        1. By Value
      3. Primary-progressive MS (PPMS)
        1. By Value
      4. Secondary-progressive MS (SPMS)
        1. By Value
      5. Progressive-relapsing MS (PRMS)
        1. By Value
    6. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Immunomodulators
          1. By Value
        3. Immunosuppressants
          1. By Value
        4. Interferons
          1. By Value
        5. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectables
          1. By Value
          2. Intramuscular
            1. Intramuscular By Value
          3. Subcutaneous
            1. Subcutaneous By Value
          4. Intravenous
            1. Intravenous By Value
        4. Infusions
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Stores
          1. By Value
      4. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Relapsing-remitting MS (RRMS)
          1. By Value
        3. Primary-progressive MS (PPMS)
          1. By Value
        4. Secondary-progressive MS (SPMS)
          1. By Value
        5. Progressive-relapsing MS (PRMS)
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Immunomodulators
        1. By Value
      3. Immunosuppressants
        1. By Value
      4. Interferons
        1. By Value
      5. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectables
        1. By Value
        2. Intramuscular
          1. Intramuscular By Value
        3. Subcutaneous
          1. Subcutaneous By Value
        4. Intravenous
          1. Intravenous By Value
      4. Infusions
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Stores
        1. By Value
    5. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Relapsing-remitting MS (RRMS)
        1. By Value
      3. Primary-progressive MS (PPMS)
        1. By Value
      4. Secondary-progressive MS (SPMS)
        1. By Value
      5. Progressive-relapsing MS (PRMS)
        1. By Value
    6. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Immunomodulators
          1. By Value
        3. Immunosuppressants
          1. By Value
        4. Interferons
          1. By Value
        5. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectables
          1. By Value
          2. Intramuscular
            1. Intramuscular By Value
          3. Subcutaneous
            1. Subcutaneous By Value
          4. Intravenous
            1. Intravenous By Value
        4. Infusions
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Stores
          1. By Value
      4. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Relapsing-remitting MS (RRMS)
          1. By Value
        3. Primary-progressive MS (PPMS)
          1. By Value
        4. Secondary-progressive MS (SPMS)
          1. By Value
        5. Progressive-relapsing MS (PRMS)
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Immunomodulators
        1. By Value
      3. Immunosuppressants
        1. By Value
      4. Interferons
        1. By Value
      5. Others
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Injectables
        1. By Value
        2. Intramuscular
          1. Intramuscular By Value
        3. Subcutaneous
          1. Subcutaneous By Value
        4. Intravenous
          1. Intravenous By Value
      4. Infusions
        1. By Value
    4. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Stores
        1. By Value
    5. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Relapsing-remitting MS (RRMS)
        1. By Value
      3. Primary-progressive MS (PPMS)
        1. By Value
      4. Secondary-progressive MS (SPMS)
        1. By Value
      5. Progressive-relapsing MS (PRMS)
        1. By Value
    6. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Immunomodulators
          1. By Value
        3. Immunosuppressants
          1. By Value
        4. Interferons
          1. By Value
        5. Others
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Injectables
          1. By Value
          2. Intramuscular
            1. Intramuscular By Value
          3. Subcutaneous
            1. Subcutaneous By Value
          4. Intravenous
            1. Intravenous By Value
        4. Infusions
          1. By Value
      3. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Stores
          1. By Value
      4. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Relapsing-remitting MS (RRMS)
          1. By Value
        3. Primary-progressive MS (PPMS)
          1. By Value
        4. Secondary-progressive MS (SPMS)
          1. By Value
        5. Progressive-relapsing MS (PRMS)
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Multiple Sclerosis Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Pfizer
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Bayer AG
    3. Teva Pharmaceutical Industries Ltd.
    4. Novartis AG
    5. Sanofi
    6. F. Hoffmann-La Roche Ltd.
    7. Celgene Corporation
    8. Acorda Therapeutics Inc.
    9. Biogen Inc.
    10. Johnson & Johnson
    11. EMD Serono
    12. Eisai Co. Ltd.
    13. Apitope
    14. AbbVie Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Multiple Sclerosis Market Size & Insights The global multiple sclerosis market size was valued at USD 26.37 billion in 2023. It is estimated to reach USD 32.93 billion by 2032, growing at a CAGR of 2.5% during the forecast period (2024
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.